Brokerages Set Stoke Therapeutics, Inc. (NASDAQ:STOK) Price Target at $23.00

Stoke Therapeutics, Inc. (NASDAQ:STOK) has earned a consensus rating of “Buy” from the ten ratings firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, eight have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $23.00.

Several equities analysts have recently issued reports on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Chardan Capital restated a “buy” rating and set a $24.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, February 19th. HC Wainwright boosted their target price on Stoke Therapeutics from $35.00 to $47.00 and gave the stock a “buy” rating in a research report on Tuesday, February 18th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research report on Tuesday, February 18th.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, CEO Edward M. Md Kaye sold 6,786 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $12.99, for a total value of $88,150.14. Following the sale, the chief executive officer now owns 61,885 shares in the company, valued at approximately $803,886.15. The trade was a 9.88 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel Jonathan Allan sold 9,696 shares of the business’s stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $12.78, for a total value of $123,914.88. Following the completion of the sale, the general counsel now owns 35,142 shares in the company, valued at $449,114.76. The trade was a 21.62 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 52,849 shares of company stock worth $688,721. Corporate insiders own 11.30% of the company’s stock.

Institutional Investors Weigh In On Stoke Therapeutics

Several institutional investors have recently bought and sold shares of STOK. KLP Kapitalforvaltning AS bought a new stake in Stoke Therapeutics in the 4th quarter valued at approximately $63,000. Teacher Retirement System of Texas bought a new stake in shares of Stoke Therapeutics during the 4th quarter worth approximately $113,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Stoke Therapeutics during the 4th quarter worth approximately $124,000. Tower Research Capital LLC TRC raised its stake in shares of Stoke Therapeutics by 70.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company’s stock worth $132,000 after purchasing an additional 4,918 shares in the last quarter. Finally, Invesco Ltd. bought a new stake in shares of Stoke Therapeutics during the 4th quarter worth approximately $133,000.

Stoke Therapeutics Trading Down 5.7 %

Stoke Therapeutics stock opened at $7.40 on Tuesday. The firm has a market capitalization of $391.96 million, a P/E ratio of -3.52 and a beta of 0.95. Stoke Therapeutics has a 1 year low of $5.60 and a 1 year high of $17.58. The business has a 50-day moving average of $10.11 and a 200-day moving average of $12.00.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.